| Second Drug Candidate Enters Expanded Development Program Under Strategic Alliance with GlaxoSmithKline
|
|
|
|
| Posted by Bill Bro at | | | |
|
| Founded by Penn State Football teammates in 2003, Lift For Life continues to build awareness and raise donations for the Kidney Cancer Association, a charity representing a medically under-served cause. The first three Lift For Life events have raised more than $80,000 for the prevention, diagnosis, and treatment of kidney cancer.
|
|
|
|
| Posted by Bill Bro at | | | |
|
| It is my hope that information from this blog will bring hope and the prospect of a better quality of life to others whose lives are touched by this disease--while we work together toward the day when ours is A World Without Kidney Cancer.
|
|
|
|
| Posted by Bill Bro at | | | |
|
| TLR9 and is currently in a Phase 2 monotherapy trial in renal cell carcinoma, and in a Phase 1/2 chemotherapy combination therapy trial in solid tumors. Idera is collaborating with Novartis for the discovery, optimization, development and commercialization of TLR9 agonist drug candidates targeting TLR9 for asthma and allergy. Idera also has selected another TLR9 agonist, IMO-2125, as a lead candidate for infectious diseases. For more information, visit www.iderapharma.com.
|
|
|
|
| Posted by Bill Bro at | | | |
|
| Until now, it has not been clear how faults in VHL can lead to the development of kidney cancer. But these findings shed light on how the faulty gene predisposes a cell to cancerous changes. |
|
|
|
| Posted by Bill Bro at | | | |
|
| The authors found a 100% technical success rate in targeting and ablation. |
|
|
|
| Posted by Bill Bro at | | | |
|
|
|
|
|
|
|
|
